The US FTC imposes remedies before clearing a merger affecting multiple markets for animal health and pharmaceutical products (Pfizer / Wyeth)

The FTC entered into a consent agreement with Pfizer Inc. and Wyeth, requiring divestiture of one entity’s U.S. operations in over 20 markets for various animal health and pharmaceutical products. The consent order, established on January 25, 2010, sets forth the divestiture of Wyeth’s U.S. business called Fort Dodge in 18 of the 20 markets. The agreement further requires Pfizer to rescind its exclusive distribution agreement concerning equine tapeworm parasiticides to the original owner and divest its own U.S. business in the market for equine herpesvirus products. Pfizer and Wyeth are two of the largest U.S. producers of animal health and pharmaceutical products, the markets for which are already highly concentrated. Both companies offer the following same cattle health products:

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Katherine Whitehead Miller, The US FTC imposes remedies before clearing a merger affecting multiple markets for animal health and pharmaceutical products (Pfizer / Wyeth), 25 January 2010, e-Competitions January 2010, Art. N° 53072

Visites 366

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues